Patents & IP Sequences | Clinical Trials | Drug Pipelines Creating reports and visualizations to support decision making with the BizInt Smart Charts product family 2019 Analytics & Visualization Meeting, Nice Diane Q. Webb, President 10 April 2019 www.bizint.com takes your search results Patents & IP Sequences | Clinical Trials | Drug Pipelines …and automatically builds tabular reports. Integrating results from different databases. And, helps you create visualizations from your reports. Tables are a powerful tool for visualizing information. Everyone understands how to read a table! Babylonian table (circa 1800 B.C.) Sports results table (circa 2010 A.D.) © 2019 BizInt Solutions, Inc | www.bizint.com 5 Tables are suitable for data sets between a few records and thousands of records (c. 2010) 1 10 100 1k 10k 100k Records Tables Statistics/Visualizations © 2019 BizInt Solutions, Inc | www.bizint.com 6 Standard technical visualizations display aggregate data… © 2019 BizInt Solutions, Inc | www.bizint.com 7 But pharma business visualizations display discrete data… © 2019 BizInt Solutions, Inc | www.bizint.com 8 Tables are suitable for data sets between a few records and thousands of records (c. 2018) 1 10 100 1k 10k 100k Business Visualizations Records Tables Statistics/Visualizations © 2019 BizInt Solutions, Inc | www.bizint.com 9 2013 II-SDV Paper: Challenges in Visualizing Pharmaceutical Business Information The Problem: Visualizations developed for scientific and patent data do not do a good job of “telling the story” when applied to drug pipeline data and often need significant changes. We returned to this topic in 2016 and 2018: bizint.com/slides © 2019 BizInt Solutions, Inc | www.bizint.com 10 Using multiple databases produces better visualizations Because of indexing variation, searches retrieve different results Additional trials returned © 2019 BizInt Solutions, Inc | www.bizint.com 11 Using multiple databases produces better visualizations And there are content variations between databases Missing end date provided by Adis More additional trials returned © 2019 BizInt Solutions, Inc | www.bizint.com 12 But using multiple databases means challenges… 1. Multiple Records for the Same Drug © 2019 BizInt Solutions, Inc | www.bizint.com 13 But using multiple databases means challenges… 2. Conflicting Data for the Same Drug © 2019 BizInt Solutions, Inc | www.bizint.com 14 But using multiple databases means challenges… 3. Terminology Variation © 2019 BizInt Solutions, Inc | www.bizint.com 15 See our “Surfing the Pipeline” papers: bizint.com/slides © 2019 BizInt Solutions, Inc | www.bizint.com 16 One of these challenges is data clean-up.. ! " # $% © 2019 BizInt Solutions, Inc | www.bizint.com 17 One of these challenges is data clean-up.. Vocabulary needs to be normalized. ! " # $% © 2019 BizInt Solutions, Inc | www.bizint.com 18 Event timeline (from clinical trials data) © 2019 BizInt Solutions, Inc | www.bizint.com 19 Piano Chart (from clinical trials data) © 2019 BizInt Solutions, Inc | www.bizint.com 20 Bullseye (created from pipeline data) Small molecules pevonedistat roniciclib LY‐3023414 trametinib porfimer sodium imatinib Marketed sunitinib napabucasin Phase 3 tazemetostat Minerval trabectedin lurbinectedin Phase 2 Cell/Gene therapies dasatinib TRC‐102 nintedanib gemcitabine prodrug Phase 1 vinorelbine defactinib CB‐839 aglatimagene besadenovec gene therapy zoledronic acid carfilzomib MesoCART anti‐mesothelin CAR raltitrexed BNC‐105P AZD‐4547 miR‐15/16 mimics pemetrexed AEOL‐10150 MTG‐201 ONCOS‐102 MTG‐202 MV‐NIS therapy amatuximab HSV‐1716 atezolizumab MV‐NIS ARGX‐110 ipilimumab Oncolytic viruses WT1 vaccine brentuximab vedotin TroVax GL‐ONC1 CAT‐5001 BGB‐A317 nivolumab NGR‐hTNF K562/GM‐CSF durvalumab durvalumab + tremelimumab galinpepimut‐S tremelimumab pegargiminase MesoPher CRS‐207 CK‐301 pembrolizumab YSCMA CBP‐501 JTCR‐016 Cancer vaccines LMB‐100 Antibodies FP‐1039 © 2019 BizInt Solutions, Inc | www.bizint.com Peptides/Proteins 21 Lessons Learned – It’s all about • There is some interest in an interactive visualization that people can explore… • But the primary requirement is for a PowerPoint slide. • An image in a PowerPoint slide is okay… • But you’d really like to create PowerPoint objects (so you can customize the presentation and make final edits.) © 2019 BizInt Solutions, Inc | www.bizint.com 22 “Piano Chart” – PowerPoint visualization Merkel cell carcinoma (MCC) pipeline: Phase for MCC and type of molecule Biological Testing Preclinical Phase I Phase II Launched Discontinued No Development Reported Merkel cell carcinoma CK-301 BGB-A317 ALT 803 avelumab lorvotuzumab mertansine ATN-161 therapies Altor BioScience Corporation ImmunoGen Vironika TG Therapeutics Celgene Merck KGaA Attenuon ETBX-051 ID-G100 cabozantinib S-malate tivantinib NantWorks Immune Design Exelixis ArQule ETBX-061 pasireotide CST-101 NantWorks Novartis NantWorks ipilimumab SIRPa-Fc F16-IL2 Bristol-Myers Squibb Co Trillium Therapeutics Philogen Option for hyperlink LTvax utomilumab MCPyV vaccine Fred Hutchinson Cancer APCure Pfizer Research Center to pipeline record Merkel cell polyomavirus nivolumab inhibitors Vironika Ono Pharmaceutical Co Ltd pazopanib GlaxoSmithKline plc pembrolizumab Merck & Co Each column contains Drugs color-coded by a Type of molecule PEN-221 Antibody the drugs in that phase Tarveda Therapeutics chosen field Biological, other sapanisertib Intellikine Cell & gene therapy Labeled by drug nametalimogene and laherparepvec Protein & peptide BioVex Inc a chosen field Small molecule therapeutic tavokinogene telsaplasmid OncoSec Medical Vaccine © 2019 BizInt Solutions, Inc | www.bizint.com 23 Annotating the Piano Chart in PowerPoint Merkel cell carcinoma (MCC) pipeline: Phase for MCC and type of molecule Biological Testing Preclinical Phase I Phase II Launched Discontinued No Development Reported Merkel cell carcinoma CK-301 BGB-A317 ALT 803 avelumab lorvotuzumab mertansine ATN-161 therapies Altor BioScience Corporation ImmunoGen Vironika TG Therapeutics Celgene Merck KGaA Attenuon ETBX-051 ID-G100 cabozantinib S-malate tivantinib NantWorks Immune Design Exelixis ArQule ETBX-061 pasireotide CST-101 NantWorks Novartis NantWorks ipilimumab SIRPa-Fc F16-IL2 Bristol-Myers Squibb Co Trillium Therapeutics Philogen LTvax utomilumab MCPyV vaccine Fred Hutchinson Cancer Add box outlines to APCure Pfizer Research Center Merkel cell polyomavirus nivolumab inhibitors indicate Key Competitors Vironika Ono Pharmaceutical Co Ltd pazopanib GlaxoSmithKline plc pembrolizumab Merck & Co Type of molecule PEN-221 Key Competitor Antibody Tarveda Therapeutics Biological, other sapanisertib Intellikine Cell & gene therapy talimogene laherparepvec Protein & peptide BioVex Inc Small molecule therapeutic tavokinogene telsaplasmid OncoSec Medical Vaccine © 2019 BizInt Solutions, Inc | www.bizint.com 24 Annotating the Piano Chart in PowerPoint Merkel cell carcinoma (MCC) pipeline: Phase for MCC and type of molecule Biological Testing Preclinical Phase I Phase II Launched Discontinued No Development Reported Merkel cell carcinoma CK-301 BGB-A317 ALT 803 avelumab lorvotuzumab mertansine ATN-161 therapies Altor BioScience Corporation ImmunoGen Vironika TG Therapeutics Celgene Merck KGaA Attenuon ETBX-051 ID-G100 cabozantinib S-malate tivantinib NantWorks Immune Design Exelixis ArQule ETBX-061 pasireotide CST-101 NantWorks Novartis NantWorks ipilimumab SIRPa-Fc F16-IL2 Bristol-Myers Squibb Co Trillium Therapeutics Philogen LTvax utomilumab MCPyV vaccine Fred Hutchinson Cancer Another way to indicate APCure Pfizer Research Center Merkel cell polyomavirus nivolumab inhibitors Key Competitors Vironika Ono Pharmaceutical Co Ltd pazopanib GlaxoSmithKline plc pembrolizumab Merck & Co Type of molecule PEN-221 Key Competitor Antibody Tarveda Therapeutics Biological, other sapanisertib Intellikine Cell & gene therapy talimogene laherparepvec Protein & peptide BioVex Inc Small molecule therapeutic tavokinogene telsaplasmid OncoSec Medical Vaccine © 2019 BizInt Solutions, Inc | www.bizint.com 25 Lessons Learned – It’s not “Easy” • Everyone wants an “easy” button! • We’ve made the actual drawing of the visualizations easy. • But a lot of data preparation is necessary -- • Filter large datasets to the most critical items • Group values to create useful categories. • Shorten labels to fit. • Apply expertise for values not in the data. © 2019 BizInt Solutions, Inc | www.bizint.com 26 Data Preparation for a drug Launch Timeline Group items into a few categories Launch Date is not a field in the data! Group items into a few colors. © 2019 BizInt Solutions, Inc | www.bizint.com 27 Piano Chart without data preparation Piano Chart - Mesothelioma Phase 1 Phase 1/2 Phase 2 Phase 3 Preregistration Launched AEOL-10150 JTCR‐016 aglatimagene besadenovec ipilimumab pemetrexed Pemetrexed ‐ CJ Healthcare AEOL‐10150 JTCR‐016 aglatimagene besadenovec ipilimumab pemetrexed pemetrexed disodium AEOL‐10150 JTCR‐016 aglatimagene besadenovec ipilimumab pemetrexed pemetrexed disodium allogeneic tumor lysate‐pulsed autologous dendritic cells JTCR‐016 amatuximab ipilimumab pemetrexed disodium allogeneic tumor lysate‐pulsed autologous dendritic cells JTCR‐016 amatuximab ipilimumab pemetrexed disodium allogeneic tumor lysate‐pulsed autologous dendritic cells pevonedistat amatuximab ipilimumab pemetrexed disodium allogeneic tumor lysate‐pulsed autologous dendritic cells pevonedistat amatuximab ipilimumab raltitrexed allogeneic tumor lysate‐pulsed autologous